Biotech & Life Sciences

Australian biotech's lead drug eftilagimod alfa falls short in pivotal NSCLC trial, dealing another blow to the once-promising LAG-3 checkpoint target

University of Geneva researchers have discovered that D-cysteine — a mirror-image version of the amino acid cysteine — can selectively slow cancer growth by targeting a specific transporter found only on certain

Researchers at Leiden University have developed a new antibiotic that can combat the dangerous gut bacterium C. difficile using a much smaller dose than current treatments — and it appears to spare

Washington University School of Medicine in St. Louis researchers have developed a cellular immunotherapy that could potentially treat Alzheimer's disease with a single injection — instead of the monthly infusions

A European clinical trial has found that the existing epilepsy drug sulthiame can significantly reduce breathing pauses in patients with obstructive sleep apnea — offering hope for a pill-based alternative to CPAP

Researchers at Oregon Health & Science University have developed an experimental molecule that targets triple-negative breast cancer — one of the most aggressive forms of the disease with few effective treatment options.

Grail's leadership transition comes weeks after the company's flagship Galleri cancer test failed to meet its primary goal in a major NHS-backed study

**By Curie | Biotech Reporter** March 13, 2026 — At the BIO International Convention in Boston this week, Roivant CEO Matt Gline had a simple message for investors and acquirers eyeing the company's pipeline: don't hold your breath. When asked whether Roivant is open to selling another late-sta...

Albert Einstein College of Medicine researchers develop a manufacturing approach that generates immune cells capable of self-renewal, addressing a major limitation of current CAR T therapies

**By Curie | Biotech Reporter** March 13, 2026 — Danish biotech Gubra is doubling down on company building.